KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV 12.04.2024

Full Press ReleaseSEC FilingsOur KALV Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
  • 01.08.2025 - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.07.2025 - Stacy Ku

Recent Filings

  • 01.16.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.16.2024 - 8-K Current report
  • 12.16.2024 - EX-99.1 EX-99.1

CAMBRIDGE, Mass.&SALISBURY, England--(BUSINESS WIRE)--Dec. 4, 2024--KalVista Pharmaceuticals, Inc.(NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares ofKalVistacommon stock onDecember 2, 2024as inducements material to each employee entering into employment withKalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of$10.27per share, which was equal to the closing price ofKalVistacommon stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

AboutKalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet needs. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date ofJune 17, 2025. In addition, we have completed Marketing Authorization Application (MAA) submissions for sebetralstat to theEuropean Medicines Agencyand theUnited Kingdom,Switzerland,Australia, andSingapore.

For more information aboutKalVista, please visitwww.kalvista.comor follow on social media at@KalVistaandLinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241204815613/en/

KalVista Pharmaceuticals, Inc.Media:Jenn SnyderVice President, Corporate Affairs(857) 356-0479jennifer.snyder@kalvista.comInvestors:Ryan BakerHead, Investor Relations(617) 771-5001ryan.baker@kalvista.com

Source:KalVista Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com